Founding President, CEO and Director of Revolution Medicines. Previously, Partner with Third Rock Ventures in its West Coast office. Prior to this, Dr. Goldsmith served as President and Chief Executive Officer of Constellation from 2009 to 2012. He previously held senior executive positions in the biotechnology industry, including Senior Executive-in-Residence at Prospect Venture Partners, CEO of Cogentus Pharmaceuticals and Senior Vice President of Genencor International. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies.
Dr. Jim Audia joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. Dr. Audia held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Prior to this role, Dr. Audia was Executive Director, Discovery Chemistry Research and Technologies, where he had global responsibility for delivery of small molecule drug candidates across all therapeutic areas. He also played a major role in companywide leadership of product strategy and portfolio management for Lilly for more than a decade. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 90 issued US patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly.
Dr. Cooper joined Constellation Pharmaceuticals in 2011 as its Chief Medical Officer. Before joining Constellation Dr. Cooper held leadership positions at Novartis Pharmaceuticals, where he was Clinical Head of Oncology Translational Medicine in Cambridge, Massachusetts, and at Millennium Pharmaceuticals, where he was Vice President of Oncology Clinical Development. Before joining the pharmaceutical industry, Dr. Cooper practiced medical oncology and hematology in various academic institutions, where he led programs in the early clinical development of novel anti-cancer compounds. His interest in cancer pharmacology, pharmacokinetics and biomarker development was developed during his tenure as a Senior Clinical Investigator in the Clinical Pharmacology and Medicine Branches of the National Cancer Institute in Bethesda, Maryland. Dr. Cooper received his M.D. from Duke University School of Medicine, which is also where he completed his residency in internal medicine and his fellowship in hematology and medical oncology.
Ms. Brenda Sousa joined Constellation as Vice President of Human Resources for Constellation in March 2010. Prior to joining Constellation Ms. Sousa was the Vice President of Human Resources and Operations at EPIX Pharmaceuticals, where she served as a member of the global executive management team and focused on the development and implementation of business strategy, operations, and organizational development for US companies with international offices. Before joining EPIX, she was Director of Human Resources for RKS Health Ventures and Spence Center for Women’s Health, a start-up venture that was ultimately purchased by Partners Healthcare. Prior to her human resources career, Ms. Sousa worked in the hospitality industry focusing on sales and marketing. Brenda joined the Board of Career Collaborative in 2004 where she initiated and served as Chair of the Employer Advisory Board. Brenda holds a Bachelor of Arts Degree from the University of Massachusetts.
Mr. Jaffe joined Constellation in April 2012 bringing over 12 years of experience in corporate finance and strategic management to his role. Previously, Mr. Jaffe served as CFO and VP of Business Development at Zafgen, a Third Rock Ventures’ portfolio company. He has also held senior positions in a number of private, venture-backed companies in the life science and cleantech space, including Alantos Pharmaceuticals, which under the leadership of Dr. Dionne, was acquired by Amgen in 2007. Prior to Alantos, Mr. Jaffe was a principal at Earlybird Venture Capital (Munich, Germany), where he supported new investments activities and existing portfolio companies. He also worked at the Boston Consulting Group, where he was a member of the pharmaceutical practice group, assisting Fortune 500 companies with strategic management issues. Mr. Jaffe holds a M.S. in molecular biology from the Massachusetts Institute of Technology, an MBA from INSEAD (Fontainebleau, France).
Dr. Sims joined Constellation Pharmaceuticals in 2008 as a founding scientist. With nearly 20 years of experience in chromatin biology and transcription, Dr. Sims helped establish Constellation’s industry-leading epigenetics platform. Dr. Sims led the discovery and translational efforts for CPI-0610, a novel BET bromodomain inhibitor currently in phase 1 clinical development for hematologic malignancies. His team’s notable work, along with others in the field, includes the discovery that BET bromodomain inhibition silences the expression of the MYC oncogene. Dr. Sims has authored more than 30 scientific publications in top-tier journals, including Science, Nature, and Cell. He received his Ph.D. in Cellular and Molecular Biology from the University of Texas at Austin and completed his postdoctoral training at UMDNJ-Robert Wood Johnson Medical School and the New York University School of Medicine.
Dr. Trojer was involved in the foundation of Constellation in early 2008 and joined the Company as a founding scientist. He has held multiple positions of increasing responsibility at Constellation. Among his many achievements, Dr. Trojer drove Constellation’s EZH2 program leading to the clinical launch of CPI-1205 currently in Ph 1 clinical trials for Lymphoma. Dr. Trojer is internationally recognized for his expertise in chromatin biology and its control of gene transcription. Dr. Trojer has authored dozens of scientific publications and is a frequent lecturer in the epigenetics space. He completed his postdoctoral studies at NYU Medical School in Dr. Danny Reinberg’s laboratory, prior to which he received both a Ph.D. in protein biochemistry and molecular biology and M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.